文献速递乳腺癌支持与姑息治疗

乳腺癌诊断时全身性炎症与2年后临床重要疲劳的生物行为模型

A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later.
PubMed 文献 · Ann Oncol · 2024-08-02

基于多模式前瞻性CANTO队列(NCT01993498),纳入1208例I-III期激素受体阳性/HER2阴性乳腺癌女性,构建整合治疗前全身性炎症标志物与临床行为因素的模型,预测诊断后2年临床重要整体癌因性疲劳。415例(34.4%)在2年时报告临床重要整体疲劳,治疗前IL-6高水平(第4四分位 vs 第1四分位)与2年整体疲劳相关(aOR 2.06,95%CI 1.40-3.03;P=0.0002;AUC=0.74)。

要点

  • 治疗前IL-6第4四分位 vs 第1四分位与2年整体疲劳相关,aOR 2.06(95%CI 1.40-3.03),AUC 0.74。
  • 治疗前疲劳 vs 无疲劳 aOR 3.99(95%CI 2.81-5.66),当前吸烟 vs 从不吸烟 aOR 1.81(95%CI 1.26-2.58)。
  • 失眠或疼痛每增加10单位分别aOR 1.08(95%CI 1.04-1.13)和1.12(95%CI 1.04-1.21)。

核心结论

  • 本研究提出一个生物行为框架,将治疗前全身性炎症与大型前瞻性乳腺癌幸存者样本中2年后临床重要癌因性疲劳相联系。

研究设计与样本

  • 多模式前瞻性CANTO队列(NCT01993498),纳入I-III期激素受体阳性/HER2阴性乳腺癌女性。
  • 主要结局为诊断后2年临床重要整体癌因性疲劳(EORTC QLQ-C30 ≥40/100),次要结局包括躯体、情绪和认知疲劳(EORTC QLQ-FA12)。
  • 治疗前候选变量在诊断时评估,包括炎症标志物(IL-1α、IL-1β、IL-2、IL-4、IL-6、IL-8、IL-10、干扰素γ、IL-1受体拮抗剂、肿瘤坏死因子α和C反应蛋白)。
  • 采用多重插补的多变量logistic回归模型,并通过100折bootstrap重采样验证。

主要发现

  • 1208例患者中415例(34.4%)在2年时报告临床重要整体疲劳。
  • 治疗前IL-6高水平(第4四分位 vs 第1四分位)与2年整体疲劳相关:aOR 2.06(95%CI 1.40-3.03);P=0.0002;AUC=0.74。
  • 治疗前IL-6高水平患者行为不健康:超重或肥胖占62.4%,平均BMI 28.0(标准差6.3 kg/m2),身体不活动者53.5%未达到世界卫生组织推荐。
  • 与2年疲劳相关的临床和行为因素包括:治疗前疲劳 vs 无治疗前疲劳 aOR 3.99(95%CI 2.81-5.66);年龄每减小1岁 aOR 1.02(95%CI 1.01-1.03);当前吸烟 vs 从不吸烟 aOR 1.81(95%CI 1.26-2.58);失眠每增加10单位 aOR 1.08(95%CI 1.04-1.13);疼痛每增加10单位 aOR 1.12(95%CI 1.04-1.21)。
  • 次要分析显示IL-2每增加1个对数单位与整体疲劳相关 aOR 1.32(95%CI 1.03-1.70),IL-10 aOR 0.73(95%CI 0.57-0.93),C反应蛋白与2年认知疲劳相关 aOR 1.42(95%CI 1.13-1.78);情绪困扰与躯体、情绪和认知疲劳一致相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to generate a model of cancer-related fatigue (CRF) of clinical importance 2 years after diagnosis of breast cancer building on clinical and behavioral factors and integrating pre-treatment markers of systemic inflammation. PATIENTS AND METHODS: Women with stage I-III hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer were included from the multimodal, prospective CANTO cohort (NCT01993498). The primary outcome was global CRF of clinical importance [European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 ≥40/100] 2 years after diagnosis (year 2). Secondary outcomes included physical, emotional, and cognitive CRF (EORTC QLQ-FA12). All pre-treatment candidate variables were assessed at diagnosis, including inflammatory markers [interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, interferon γ, IL-1 receptor antagonist, tumor necrosis factor-α, and C-reactive protein], and were tested in multivariable logistic regression models implementing multiple imputation and validation by 100-fold bootstrap resampling. RESULTS: Among 1208 patients, 415 (34.4%) reported global CRF of clinical importance at year 2. High pre-treatment levels of IL-6 (quartile 4 versus 1) were associated with global CRF at year 2 [adjusted odds ratio (aOR): 2.06 (95% confidence interval [CI] 1.40-3.03); P = 0.0002; area under the receiver operating characteristic curve = 0.74]. Patients with high pre-treatment IL-6 had unhealthier behaviors, including being frequently either overweight or obese [62.4%; mean body mass index 28.0 (standard deviation 6.3 kg/m2)] and physically inactive (53.5% did not meet World Health Organization recommendations). Clinical and behavioral associations with CRF at year 2 included pre-treatment CRF [aOR versus no pre-treatment CRF: 3.99 (95% CI 2.81-5.66)], younger age [aOR per 1-year decrement: 1.02 (95% CI 1.01-1.03)], current tobacco smoking [aOR versus never: 1.81 (95% CI 1.26-2.58)], and worse insomnia or pain [aOR per 10-unit increment: 1.08 (95% CI 1.04-1.13), and 1.12 (95% CI 1.04-1.21), respectively]. Secondary analyses indicated additional associations of IL-2 [aOR per log-unit increment: 1.32 (95% CI 1.03-1.70)] and IL-10 [0.73 (95% CI 0.57-0.93)] with global CRF and of C-reactive protein [1.42 (95% CI 1.13-1.78)] with cognitive CRF at year 2. Emotional distress was consistently associated with physical, emotional, and cognitive CRF. CONCLUSIONS: This study proposes a bio-behavioral framework linking pre-treatment systemic inflammation with CRF of clinical importance 2 years later among a large prospective sample of survivors of breast cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Di Meglio A, Havas J, Pagliuca M, et al. A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later. Ann Oncol. 2024. PMID: 39098454. doi:10.1016/j.annonc.2024.07.728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。